U.S. biotechnology company Amgen Inc (AMGN.O) is expanding in Brazil, announcing on Friday it had acquired privately-held Bergamo for about $215 million while reacquiring rights in the country to several Amgen products. Bergamo, which had $80 million in revenue last year, supplies medicines to the Brazilian hospital sector and has capabilities in oncology, Amgen said. Amgen also agreed with Hypermarcas (HYPE3.SA), a maker of personal hygiene products, to reacquire Brazilian rights to several products, including its Vectibix cancer drug.
Source
